The content on this site is intended for healthcare professionals only
Prof Gordon McVie discusses November's top news articles including:
FDA approves obinutuzumab for chronic lymphocytic leukaemia
NCRI 2013: Redirecting our immune cells to help fight children's cancer
FDA pulls ponatinib approval due to blood clots and narrowing of blood vessels
Breast cancer survivorship
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Latest in EGFR mutated NSCLC
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
